World Journal of Gastroenterology, Год журнала: 2025, Номер 31(11)

Опубликована: Март 12, 2025

In this editorial, we critically evaluate the recent article by Niu et al , which explores potential of phospholipase D2 (PLD2) as a biomarker for stratifying disease severity in acute pancreatitis (AP). AP is clinically heterogeneous inflammatory condition that requires reliable biomarkers early and accurate classification severity. PLD2, an essential regulator neutrophil migration responses, has emerged promising candidate. Although current such C-reactive protein procalcitonin provide general indications inflammation, they lack specificity regarding molecular mechanisms underlying progression. Recent studies, including research conducted suggest inverse correlation between PLD2 expression severity, offering both diagnostic insights mechanistic understanding. This editorial evaluates role broader context research. Evidence indicates decreased levels are associated with increased chemotaxis cytokine release, contributing to pancreatic systemic inflammation. However, several challenges remain, need large-scale validation functional studies establish causation, standardization measurement protocols. Additionally, further investigation into temporal dynamics its variability across diverse populations warranted. Looking ahead, holds revolutionize management integrating diagnostics precision medicine. The utilization multi-omics approaches advancements platforms could position fundamental diagnosis, prognosis, potentially therapeutic targeting. While promising, it crucial conduct critical evaluations rigorous validations PLD2’s ensure efficacy improving patient outcomes.

Язык: Английский